DBV Technologies
Research DBV Technologies (DBVT) on Bullrun: market cap USD 885.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDBVT
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 885.97M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 50.40M
- Free cash flow-USD 53.00M
Valuation Snapshot
latest market cap is USD 885.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 5.64M | -USD 146.95M | -USD 121.71M | n/a | -1.05 | USD 194.20M | USD 7.99M | USD 168.80M |
| FY2024 | USD 4.15M | -USD 113.92M | -USD 106.81M | n/a | -1.17 | USD 32.46M | USD 7.80M | USD 27.40M |
| FY2023 | USD 15.73M | -USD 72.71M | -USD 80.33M | n/a | -0.76 | USD 141.37M | USD 6.55M | USD 140.19M |
| FY2022 | USD 4.84M | USD 96.27M | -USD 56.42M | n/a | -1.24 | USD 209.19M | USD 5.30M | USD 194.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 885.97M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 903.28M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 63.39M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 36.74M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 57.51M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 35.16M | n/a | n/a | n/a |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is DBV Technologies's market cap?
DBV Technologies's market capitalization is USD 885.97M.
What does DBV Technologies do?
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease.